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Cyclophosphamide is one of the standard therapies for lupus, especially lupus nephritis based on its 
immunosuppressive effect. However, cyclophosphamide is also known as a nephrotoxic agent. Therefore, 
this research was aimed to measure the effect of cyclophosphamide at the dose that comparable to the 
human dose of 1 mg/kg BW on the kidney of lupus mice induced by means of 2,6,10,14-
tetramethylpentadecane (TMPD). In this research, the IL-6 as a pro-inflammatory cytokine was tested by 
using flow cytometry method. In addition, the structural damage of the kidney tissues was assessed by 
means of Moroni’s kidney organ scoring method for lupus. The result showed that cyclophosphamide 
reduced the IL-6 significantly with the value of 36.72±22.79% for the TMPD-treated group; 32.59±9.97% 
for the cyclophosphamide group; and 30.25±4.48% for the naïve group. Moreover, the damages of the 
kidney tissues on the cyclophosphamide group were more severe than the TMPD-treated group. In 
conclusion, despite its anti-inflammatory effect which is useful for lupus, cyclophosphamide has a severe 
nephrotoxic effect which harms the patient. The effects may be a cause of the long interval use of 
cyclophosphamide. It can be a consideration for the further research and the next revision of the guideline 
for lupus nephritis treatment.  
 
Keywords:  cyclophosphamide, nephrotoxic, lupus treatment, IL-6, lupus mice  
 
 
Submitted: 22 October 2020 Accepted: 26 June 2021 DOI: https://doi.org/10.25026/jtpc.v5i3.289      
 
 
Journal of Tropical Pharmacy and Chemistry 
Nephrotoxicity Risk of Cyclophosphamide in Lupus Model  
 
 
J. Trop. Pharm. Chem. 2021. Vol 5. No. 3.   
p-ISSN: 2087-7099; e-ISSN: 2407-6090 
219 
1. Introduction 
Cyclophosphamide is a non-selective 
immunosuppressive agent for lupus. It is widely 
used for lupus nephritis patients since 
cyclophosphamide is one standard for moderate 
to severe lupus treatment beside 
corticosteroids [1–4]. Cyclophosphamide has a 
non-specific immunosuppressive activity for 
lupus nephritis patients in a dose of 1-3 mg/kg 
BW [2, 5]. However, like other drugs for lupus, 
cyclophosphamide is used in a long term 
treatment, so there are big chances for the side 
effects to appear.  
One of cyclophosphamide side effects is 
nephrotoxicity [6,7]. It is opposite to the aim of 
cyclophosphamide as the lupus nephritis 
standard treatment. Therefore, this research 
observed the effect of the cyclophosphamide on 
lupus nephritis. The mice model induced by 
means of 2,6,10,14-tetramethylpentadecane 
(TMPD) to became the severe lupus nephritis 
mice with the severity marker of proteinuria at 
the level of ++ (100mg/dL) [8–11]. The mice 
were treated by using cyclophosphamide for 
three weeks, and then the spleen cells were 
isolated to measure the IL-6 relative 
percentages. Finally, the mice kidneys were 
prepared for the structural tissue damage 
observation. 
 
2. Experimental section  
2.1 Materials 
The materials used in this research were 
TMPD with the brand of Pristane was obtained 
from a Sigma-Aldrich distributor in Singapore. 
Then, cyclophosphamide with the purity of 98% 
was obtained from Kimia Farma, Indonesia; 
female BALB/c mice aged four weeks and 
pathogen-free species have been achieved from 
LPPT Unit 4, Gadjah Mada University, Indonesia.  
Other materials such as antibody anti-IL-6 
and anti-CD68 from Biogenesis were obtained 
from Molecular Biology Laboratory, Brawijaya 
University, Indonesia. 
2.2 Methods 
The female Balb/c mice used were seven 
weeks old when treated by using 0.5 mL TMPD 
intraperitoneal injection. The induction time 
lasted for six months. At the end of the induction 
time, the semi-quantitative data of proteinuria 
level showed a severe lupus manifestation. 
Then, the mice were divided into three 
experimental groups (n=5 per group), i.e., the 
TMPD-treated group, the cyclophosphamide 
group, and the naïve control group. The 
compounds tested were orally administered on 
the daily treatment until 21 days. Finally, the 
mice were sacrificed. The CD68+IL-6+ T cells 
were measured by using flow cytometer BD 
FACS Calibur. Then, the data were analyzed by 
using BD CellQuest program. The data was 
analyzed by facilitating of Oneway ANOVA by 
means of SPSS Statistics 22 version. 
Furthermore, the kidney tissues were observed 
by facilitating of hematoxylin-eosin (HE) 
staining and the use of microscope Olympus 
CKX41. The assessment was performed by 
means of Moroni scoring system. This research 
procedure was approved by local ICUC of 
Faculty of Veterinary Medicine, Universitas 
Airlangga, Indonesia with the number of 512-
KE. 
 
3. Results and Discussion 
The principle of current lupus nephritis 
treatment is reducing the manifestations. 
Cyclophosphamide has a likely non-selective 
immunosuppressive effect which is beneficially 
used in lupus nephritis [1,2,12]. Therefore it 
becomes the standard treatment for severe 
lupus nephritis. The outcome of the 
immunosuppressive effect is the inhibition of 
pro-inflammatory biomarkers, such as IL-6.  
In the present study, the IL-6 was 
measured by using flow cytometry method. The 
relative percentages of IL-6 expressed by IL-6-
producing cells were analyzed well so that the 
difference between the TMPD-treated group, 
the cyclophosphamide group, and the naïve 
group was calculated as shown in Figure 1.    
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Figure 1 The relative percentage of IL-6+ of all producing cells in (a) TMPD-treated group, (b) cyclophosphamide group, and (c) 




   
                              (a)                                              (b)                                                              (c) 
Figure 2 The structural damages of the kidney tissues of the (a) TMPD-treated group, (b) cyclophosphamide group, and (c) naïve 




The results show that the 
cyclophosphamide reduces the pro-
inflammatory cytokine IL-6 significantly 
(p<0.05). It is a good sign of its efficacy to 
maintain the lupus patient’s condition [13–15]. 
Although there was also a macrophage 
autophagy process which can inhibit the IL-6 
secretion by itself, the IL-6 as the result of 
adaptive immune response seemed decreased 
since the total IL-6 assessment in this research 
calculates all IL-6 from all sources.   
Figure 2a and 2b show the thickening of 
the glomerular basement membrane, the 
proliferation of inflammatory cells in the 
glomeruli, and also the unregular structure 
pattern of outside areas of glomeruli compared 
to naïve mice (Figure 2c). The glomeruli of the 
TMPD-treated mice are partially attached to the 
Bowman’s capsule area and then make the 
Bowman’s space narrower than normal. It leads 
the low filtration function of the glomeruli 
because of the damage of its podocytes [17–19]. 
Unfortunately, the cyclophosphamide cannot 
heal the inflamed glomeruli, but the worse sign 
of glomeruli attachment is seen in Figure 2b. 
The Bowman’s spaces are too narrow, and some 
of the glomeruli are fully attached to the outside 
areas lead to the total damage of filtration 
function of the glomeruli [20–22]. The figures 
represent all mice in all groups tested.  
Furthermore, the kidney tissue damage 





32.59±9.97 %* 36.72±2.79 % 
30.25±4.48 % 
(a) (b) (c) 
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using Moroni’s scoring method [23] for lupus 




Table 1 Assessment of the structural damages of the 
kidneys in the three groups tested  
Groups Mean of severity grade according 
to Moroni’s scoring method ± SD 








The result of cyclophosphamide group 
shows the grade of kidney-structural damage 
which is more severe significantly (p<0.05) than 
the TMPD-treated group. This data supports the 
descriptive data. It means the nephrotoxicity of 
cyclophosphamide might contribute in 
damaging the kidney structure and function. In 
spite of its effectiveness in maintaining immune 
system in lupus [24-26] the long term-use of 
cyclophosphamide results in a serious problem 
in the kidney so its use must be restricted.  
Another issue in lupus nephritis is the 
limited choice of drugs used [27, 28]. It is 
overwhelming since the patients need the 
treatment all time. The suggestion is the use of 
other immunosuppressive drugs which are not 
nephrotoxic, like corticosteroids since it is also 
included in the guideline of lupus nephritis 
treatment.  
However, the further research to support 
this research are necessary. The development of 
lupus nephritis drugs is also needed since the 
prevalence of lupus increase in this last decade.    
 
4. Conclusion  
Beside its immunosuppressive activity, 
cyclophosphamide in a long term use has side 
effects on inflammation and damage the 
structure of kidney tissue.  
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